Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3729) 3729
antineoplastic combined chemotherapy protocols - therapeutic use (2821) 2821
ifosfamide - administration & dosage (2647) 2647
science & technology (2515) 2515
life sciences & biomedicine (2499) 2499
female (2441) 2441
male (2325) 2325
adult (2063) 2063
middle aged (1888) 1888
oncology (1825) 1825
biological and medical sciences (1528) 1528
medical sciences (1521) 1521
chemotherapy (1406) 1406
aged (1345) 1345
etoposide - administration & dosage (1131) 1131
cisplatin - administration & dosage (1070) 1070
pharmacology. drug treatments (1066) 1066
ifosfamide - therapeutic use (1050) 1050
ifosfamide (999) 999
antineoplastic agents (984) 984
treatment outcome (919) 919
adolescent (878) 878
ifosfamide - adverse effects (876) 876
doxorubicin - administration & dosage (875) 875
antineoplastic combined chemotherapy protocols - adverse effects (872) 872
combined modality therapy (777) 777
child (605) 605
lung neoplasms - drug therapy (603) 603
vincristine - administration & dosage (509) 509
prognosis (494) 494
survival rate (487) 487
carboplatin - administration & dosage (477) 477
cancer (458) 458
drug administration schedule (458) 458
cyclophosphamide - administration & dosage (443) 443
disease-free survival (433) 433
neoplasm staging (414) 414
child, preschool (410) 410
antineoplastic combined chemotherapy protocols - administration & dosage (406) 406
survival analysis (399) 399
tumors (395) 395
remission induction (383) 383
sarcoma - drug therapy (379) 379
hematology (363) 363
retrospective studies (353) 353
follow-up studies (341) 341
methotrexate - administration & dosage (336) 336
chemotherapy, adjuvant (331) 331
mesna - administration & dosage (315) 315
bone neoplasms - drug therapy (294) 294
carcinoma, non-small-cell lung - drug therapy (289) 289
pharmacology & pharmacy (287) 287
antineoplastic agents, alkylating - therapeutic use (280) 280
salvage therapy (278) 278
cisplatin (267) 267
young adult (265) 265
animals (263) 263
pediatrics (262) 262
abridged index medicus (259) 259
dose-response relationship, drug (256) 256
antineoplastic agents - therapeutic use (255) 255
etoposide - therapeutic use (251) 251
paclitaxel - administration & dosage (250) 250
prospective studies (246) 246
cisplatin - adverse effects (240) 240
etoposide - adverse effects (235) 235
infant (235) 235
cisplatin - therapeutic use (230) 230
care and treatment (229) 229
antineoplastic agents, alkylating - administration & dosage (222) 222
etoposide (221) 221
neoplasms - drug therapy (219) 219
sarcoma (219) 219
medicine & public health (218) 218
doxorubicin - therapeutic use (217) 217
surgery (208) 208
soft tissue neoplasms - drug therapy (204) 204
time factors (204) 204
bleomycin - administration & dosage (203) 203
osteosarcoma - drug therapy (203) 203
neoplasm recurrence, local - drug therapy (199) 199
vinblastine - administration & dosage (199) 199
neoplasm metastasis (181) 181
drug evaluation (179) 179
carcinoma, small cell - drug therapy (178) 178
infusions, intravenous (178) 178
aged, 80 and over (177) 177
epirubicin - administration & dosage (177) 177
doxorubicin (174) 174
antineoplastic agents, alkylating - adverse effects (171) 171
lymphoma, non-hodgkin - drug therapy (171) 171
testicular neoplasms - drug therapy (170) 170
cyclophosphamide - therapeutic use (168) 168
risk factors (166) 166
lung neoplasms - mortality (165) 165
lung neoplasms - pathology (165) 165
dactinomycin - administration & dosage (162) 162
ovarian neoplasms - drug therapy (159) 159
mesna - therapeutic use (156) 156
neoadjuvant therapy (156) 156
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3683) 3683
Japanese (166) 166
German (109) 109
French (72) 72
Chinese (37) 37
Spanish (18) 18
Polish (14) 14
Italian (12) 12
Russian (6) 6
Bulgarian (2) 2
Czech (2) 2
Hebrew (2) 2
Hungarian (2) 2
Lithuanian (2) 2
Danish (1) 1
Dutch (1) 1
Finnish (1) 1
Korean (1) 1
Norwegian (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Outcomes of patients with double-hit lymphoma who achieve first complete remission
by Landsburg, Daniel J and Mato, Anthony R and Gerson, James N and Barta, Stefan K and Falkiewicz, Marissa K and Howlett, Christina and Feldman, Tatyana and Maly, Joseph and Blum, Kristie A and Hill, Brian T and Li, Shaoying and Medeiros, L. Jeffrey and Torka, Pallawi and Hernandez-Ilizaliturri, Francisco and Lue, Jennifer K and Amengual, Jennifer E and Reddy, Nishitha M and Singavi, Arun and Fenske, Timothy S and Chavez, Julio C and Kaplan, Jason B and Behdad, Amir and Petrich, Adam M and Peace, David J and Nathan, Sunita and Bast, Martin A and Vose, Julie M and Olszewski, Adam J and Costa, Cristiana and Lansigan, Frederick and Calzada, Oscar and Cohen, Jonathon B and Rivera, Xavier and Persky, Daniel O and Cassaday, Ryan D
Journal of clinical oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 20, pp. 2260 - 2267
Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Recurrence | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Transplantation, Autologous | Methotrexate - therapeutic use | Lymphoma, B-Cell - genetics | Cyclophosphamide - therapeutic use | Stem Cell Transplantation | Female | Ifosfamide - therapeutic use | Etoposide - therapeutic use | Survival Rate | Remission Induction | Cytarabine - administration & dosage | Proto-Oncogene Proteins c-bcl-6 - genetics | Disease-Free Survival | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Methotrexate - administration & dosage | Proto-Oncogene Proteins c-myc - genetics | Proto-Oncogene Proteins c-bcl-2 - genetics | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Index Medicus | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Current approaches to the management of pediatric hodgkin lymphoma
by Freed, Jennifer and Kelly, Kara M
Paediatric drugs, ISSN 1174-5878, 2010, Volume 12, Issue 2, pp. 85 - 98
Anthracyclines, therapeutic use | Chlormethine, therapeutic use | Alkylating-agents, therapeutic use | Brentuximab-vedotin, therapeutic use | Cisplatin, therapeutic use | Bortezomib, therapeutic use | Bleomycin, therapeutic use | Children | Index Medicus
Journal Article
Details down arrow
3. Full Text How I treat Burkitt lymphoma in adults
by Jacobson, Caron and LaCasce, Ann
Blood, ISSN 0006-4971, 11/2014, Volume 124, Issue 19, pp. 2913 - 2920
Life Sciences & Biomedicine | Hematology | Science & Technology | Doxorubicin - therapeutic use | Nasopharyngeal Neoplasms - genetics | Translocation, Genetic | Ifosfamide - therapeutic use | Prognosis | Cytarabine - therapeutic use | Humans | Etoposide - therapeutic use | Male | Burkitt Lymphoma - diagnosis | Methotrexate - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Burkitt Lymphoma - genetics | Adult | Nasopharyngeal Neoplasms - drug therapy | Nasopharyngeal Neoplasms - diagnosis | Prednisone - therapeutic use | Burkitt Lymphoma - drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14
by Hertzberg, Mark and Gandhi, Maher K and Trotman, Judith and Butcher, Belinda and Taper, John and Johnston, Amanda and Gill, Devinder and Ho, Shir-Jing and Cull, Gavin and Fay, Keith and Chong, Geoff and Grigg, Andrew and Lewis, Ian D and Milliken, Sam and Renwick, William and Hahn, Uwe and Filshie, Robin and Kannourakis, George and Watson, Anne-Marie and Warburton, Pauline and Wirth, Andrew and Seymour, John F and Hofman, Michael S and Hicks, Rodney J and ALLG and Australasian Leukaemia Lymphoma Group (ALLG)
Haematologica (Roma), ISSN 0390-6078, 2017, Volume 102, Issue 2, pp. 356 - 363
Life Sciences & Biomedicine | Hematology | Science & Technology | Doxorubicin - therapeutic use | Cytarabine - therapeutic use | Humans | Middle Aged | Podophyllotoxin - therapeutic use | Male | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Young Adult | Carmustine - therapeutic use | Lymphoma, Large B-Cell, Diffuse - diagnostic imaging | Lymphoma, Large B-Cell, Diffuse - therapy | Adult | Female | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Positron-Emission Tomography - methods | Lymphoma, Large B-Cell, Diffuse - mortality | Rituximab - administration & dosage | Retreatment | Ifosfamide - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Fluorodeoxyglucose F18 | Aged | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphoma
by Landsburg, Daniel J and Petrich, Adam M and Abramson, Jeremy S and Sohani, Aliyah R and Press, Oliver and Cassaday, Ryan and Chavez, Julio C and Song, Kevin and Zelenetz, Andrew D and Gandhi, Mitul and Shah, Namrata and Fenske, Timothy S and Jaso, Jesse and Medeiros, L. Jeffrey and Yang, David T and Nabhan, Chadi
Cancer, ISSN 0008-543X, 02/2016, Volume 122, Issue 4, pp. 559 - 564
BCL6 (B‐cell lymphoma 6) | non‐Hodgkin lymphoma | gene rearrangement | BCL2 (B‐cell lymphoma 2) | MYC | BCL6 (B-cell lymphoma 6) | non-Hodgkin lymphoma | BCL2 (B-cell lymphoma 2) | Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Prognosis | Cytarabine - therapeutic use | Humans | Middle Aged | Male | Methotrexate - therapeutic use | Bone Marrow Neoplasms - genetics | Lymphoma, B-Cell - genetics | Cyclophosphamide - therapeutic use | Lymphoma, Non-Hodgkin - pathology | Burkitt Lymphoma - pathology | Burkitt Lymphoma - genetics | Female | Burkitt Lymphoma - drug therapy | Databases, Factual | Lymphoma, B-Cell - drug therapy | Lymphoma, Non-Hodgkin - drug therapy | Ifosfamide - therapeutic use | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Central Nervous System Neoplasms - genetics | Etoposide - therapeutic use | Survival Rate | Germinal Center - pathology | Lymphoma, Non-Hodgkin - genetics | DNA-Binding Proteins - genetics | Genes, bcl-2 - genetics | Rituximab - administration & dosage | Central Nervous System Neoplasms - pathology | Dexamethasone - therapeutic use | Bone Marrow Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Gene Rearrangement | Genes, myc - genetics | Lymphoma, B-Cell - pathology | Vincristine - therapeutic use | Bone Marrow Neoplasms - drug therapy | Central Nervous System Neoplasms - drug therapy | Lymphoma, Large B-Cell, Diffuse - genetics | Prednisone - therapeutic use | Cohort Studies | Proto-Oncogene Proteins c-bcl-6 | Care and treatment | Chemotherapy | Usage | Non-Hodgkin's lymphomas | Diagnosis | Research | Oncogenes | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory hodgkin lymphoma undergoing autologous stem cell transplantation
by Eroglu, Celalettin and Kaynar, Leylagül and Orhan, Okan and Keklik, Muzaffer and Sahin, Cem and Yildiz, Oʇuz G and Mentes, Selahattin and Kurnaz, Fatih and Aslan, Dicle and Sivgin, Serdar and Soyuer, Serdar and Eser, Bülent and Cetin, Mustafa and Unal, Ali
American journal of clinical oncology, ISSN 0277-3732, 02/2015, Volume 38, Issue 1, pp. 68 - 73
chemoradiotherapy | autologous stem cell transplantation | Hodgkin lymphoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Methylprednisolone - therapeutic use | Cytarabine - therapeutic use | Dacarbazine - therapeutic use | Hodgkin Disease - pathology | Humans | Middle Aged | Male | Transplantation, Autologous | Melphalan - therapeutic use | Vinblastine - therapeutic use | Neoplasm Recurrence, Local - pathology | Young Adult | Carmustine - therapeutic use | Bleomycin - therapeutic use | Carboplatin - therapeutic use | Mediastinal Neoplasms - therapy | Adult | Female | Retrospective Studies | Chemoradiotherapy - methods | Ifosfamide - therapeutic use | Neoplasm Recurrence, Local - therapy | Etoposide - therapeutic use | Treatment Outcome | Dexamethasone - therapeutic use | Stem Cell Transplantation - methods | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mediastinal Neoplasms - pathology | Hodgkin Disease - therapy | Adolescent | Neoplasm Staging | Cohort Studies | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol
by Ferrari, S and Sundby Hall, K and Luksch, R and Tienghi, A and Wiebe, T and Fagioli, F and Alvegard, T.A and Brach del Prever, A and Tamburini, A and Alberghini, M and Gandola, L and Mercuri, M and Capanna, R and Mapelli, S and Prete, A and Carli, M and Picci, P and Barbieri, E and Bacci, G and Smeland, S
Annals of oncology, ISSN 0923-7534, 05/2011, Volume 22, Issue 5, pp. 1221 - 1227
chemotherapy-induced necrosis | Ewing sarcoma | high-dose chemotherapy | Chemotherapy-induced necrosis | High-dose chemotherapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Diseases of the osteoarticular system | Tumors of striated muscle and skeleton | Myeloablative Agonists - therapeutic use | Bone Neoplasms - mortality | Doxorubicin - therapeutic use | Bone Neoplasms - therapy | Sarcoma, Ewing - therapy | Humans | Child, Preschool | Male | Sarcoma, Ewing - mortality | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Young Adult | Dactinomycin - therapeutic use | Adult | Female | Child | Ifosfamide - therapeutic use | Busulfan - therapeutic use | Kaplan-Meier Estimate | Etoposide - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - therapeutic use | Peripheral Blood Stem Cell Transplantation | Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Cancer and Oncology | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
by Xiao, Yang and Liu, Jun and Liu, Yang-Chen and Huang, Xin-En and Guo, Jian-Xong and Wei, Wei
Asian Pacific journal of cancer prevention : APJCP, ISSN 1513-7368, 2014, Volume 15, Issue 9, pp. 3951 - 3954
Nausea/vomitting | Chemotherapy | Electronic anti-nausea instrument | Palonosetron | Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Carmustine - therapeutic use | Quinuclidines - therapeutic use | Antineoplastic Agents - adverse effects | Nausea - therapy | Antiemetics - therapeutic use | Adult | Vomiting - prevention & control | Carmustine - adverse effects | Ifosfamide - therapeutic use | Ifosfamide - adverse effects | Serotonin Antagonists - therapeutic use | Neoplasms - drug therapy | Nausea - prevention & control | Serotonin 5-HT3 Receptor Antagonists - therapeutic use | Cisplatin - therapeutic use | Electric Stimulation Therapy - methods | Cisplatin - adverse effects | Epirubicin - therapeutic use | Isoquinolines - therapeutic use | Aged | Vomiting - therapy | Doxorubicin - adverse effects | Epirubicin - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text AMC 048: Modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma
by Noy, Ariela and Lee, Jeannette Y and Cesarman, Ethel and Ambinder, Richard and Baiocchi, Robert and Reid, Erin and Ratner, Lee and Wagner-Johnston, Nina and Kaplan, Lawrence and AIDS Malignancy Consortium
Blood, ISSN 0006-4971, 07/2015, Volume 126, Issue 2, pp. 160 - 166
Life Sciences & Biomedicine | Hematology | Science & Technology | HIV-1 | Doxorubicin - therapeutic use | Cytarabine - therapeutic use | HIV Infections - epidemiology | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cytarabine - adverse effects | Methotrexate - therapeutic use | Cyclophosphamide - adverse effects | Burkitt Lymphoma - epidemiology | Cyclophosphamide - therapeutic use | Young Adult | Adult | Female | Burkitt Lymphoma - drug therapy | Ifosfamide - therapeutic use | Etoposide - adverse effects | Ifosfamide - adverse effects | Rituximab | Etoposide - therapeutic use | Treatment Outcome | Burkitt Lymphoma - etiology | Antiretroviral Therapy, Highly Active | Methotrexate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | HIV Infections - complications | Vincristine - therapeutic use | Vincristine - adverse effects | HIV Infections - drug therapy | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation
by Luksch, R and Tienghi, A and Hall, K. Sundby and Fagioli, F and Picci, P and Barbieri, E and Gandola, L and Eriksson, M and Ruggieri, P and Daolio, P and Lindholm, P and Prete, A and Bisogno, G and Tamburini, A and Grignani, G and Abate, M.E and Podda, M and Smeland, S and Ferrari, S
Annals of oncology, ISSN 0923-7534, 11/2012, Volume 23, Issue 11, pp. 2970 - 2976
total-lung irradiation | lung metastases | Ewing's sarcoma | high-dose chemotherapy | Lung metastases | Total-lung irradiation | High-dose chemotherapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Pharmacology. Drug treatments | Diseases of the osteoarticular system | Tumors of striated muscle and skeleton | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pneumology | Myeloablative Agonists - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Bone Neoplasms - therapy | Sarcoma, Ewing - therapy | Humans | Bone Neoplasms - secondary | Child, Preschool | Lung Neoplasms - radiotherapy | Male | Antineoplastic Agents - therapeutic use | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Stem Cell Transplantation | Young Adult | Lung Neoplasms - secondary | Neoplasm Metastasis - drug therapy | Adult | Female | Child | Ifosfamide - therapeutic use | Busulfan - therapeutic use | Neoplasm Metastasis - radiotherapy | Etoposide - therapeutic use | Combined Modality Therapy | Lung Neoplasms - therapy | Sarcoma, Ewing - drug therapy | Sarcoma, Ewing - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - therapeutic use | Sarcoma, Ewing - radiotherapy | Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | total-lung | Klinisk medicin | Cancer and Oncology | irradiation | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study
by Selle, F and Wittnebel, S and Biron, P and Gravis, G and Roubaud, G and Bui, B.N and Delva, R and Bay, J.O and Fléchon, A and Geoffrois, L and Caty, A and Soares, D.G and de Revel, T and Fizazi, K and Gligorov, J and Micléa, J.M and Dubot, C and Provent, S and Temby, I and Gaulet, M and Horn, E and Brindel, I and Lotz, J.P
Annals of oncology, ISSN 0923-7534, 09/2014, Volume 25, Issue 9, pp. 1775 - 1782
germ-cell tumors | hematopoietic stem-cell transplantation | nonrefractory patients | TAXIF II trial | high-dose chemotherapy | Nonrefractory patients | Germ-cell tumors | High-dose chemotherapy | Hematopoietic stem-cell transplantation | Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Thiotepa - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Carboplatin - adverse effects | Young Adult | Carboplatin - therapeutic use | Antineoplastic Agents - adverse effects | Treatment Failure | Adult | Female | Neoplasms, Germ Cell and Embryonal - drug therapy | Neoplasms, Germ Cell and Embryonal - mortality | Ifosfamide - therapeutic use | Etoposide - adverse effects | Ifosfamide - adverse effects | Hematopoietic Stem Cell Transplantation | Paclitaxel - adverse effects | Etoposide - therapeutic use | Paclitaxel - therapeutic use | Disease-Free Survival | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Cisplatin - adverse effects | Epirubicin - therapeutic use | Neoplasms, Germ Cell and Embryonal - surgery | Epirubicin - adverse effects | Thiotepa - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights